FDA grants pre-market clearance for SBi's rHead Extended Stem

Small Bone Innovations, Inc. (SBi), an orthopedics company focused exclusively on serving patients and their physicians with technologies and treatments for joint repair (arthroplasty) and trauma reconstruction around the small bones & joints of the thumb, fingers, hand, wrist, elbow, toes and foot & ankle announced that it has received 510(k) pre-market clearance notification from the U.S. Food and Drug Administration (FDA) for the radial Head (rHead™) Extended Stem to be used in the correction of complex elbow instabilities and/or elbow reconstruction.

The rHead Extended Stem further expands SBi's upper limb product line. It is intended to be used in conjunction with SBi's Elbow Management System (EMS), which incorporates an algorithmic approach to provide surgeons an array of solutions for treating elbow fractures. Addition of the rHead Extended Stem to EMS increases treatment options for elbow fractures where fixation may be inadequate.

Anthony G. Viscogliosi, Chairman & CEO of SBi, said: "The rHead Extended Stem was designed to be easily integrated with the EMS and provides surgeons greater flexibility to treat complex elbow fractures. The addition of the extended stem to our product portfolio is another step towards creating the most attractive, anatomically-focused product portfolio dedicated to restoring form, function and motion while alleviating pain in upper limb joints. This also reinforces SBi's commitment to work with key opinion leaders to continue to provide product solutions that serve the full range of clinical needs of surgeons and their patients."

SBi has been attracting considerable attention in recent months in both the financial and the orthopedics sector. Out of nearly 5,200 companies considered, SBi was the only orthopedic company on the list of the top 50 U.S. VC-backed companies in the Wall Street Journal article "Sizing Up Promising Young Firms" on March 9, 2010. Additionally, SBi was the 7th highest ranked healthcare company and was 24th amongst all 50 companies highlighted.

SBi closed on $12 million in Series E funding from Olympus Corporation in March 2010. The company secured a $30mm debt facility from Fortress Investment Group to fund accelerated business expansion and refinance existing indebtedness in November 2009. The company in mid 2009 closed on $144 million in Series D and Series C funding from a host of investors including, Goldman, Sachs & Co., Khazanah Nasional Berhad (the investment firm of the Government of Malaysia), Malaysian Technology Development Corporation (MTDC), an integrated Malaysian-based venture capital company, The Family Office of Bahrain, Viscogliosi Brothers, LLC, Trevi Health Ventures, NGN Capital, 3i Group, and TGap Ventures, among others.

Source:

 Small Bone Innovations, Inc

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Evident Corporation - Life Sciences. (2019, June 20). FDA grants pre-market clearance for SBi's rHead Extended Stem. News-Medical. Retrieved on November 21, 2024 from https://www.news-medical.net/news/20110124/FDA-grants-pre-market-clearance-for-SBis-rHead-Extended-Stem.aspx.

  • MLA

    Evident Corporation - Life Sciences. "FDA grants pre-market clearance for SBi's rHead Extended Stem". News-Medical. 21 November 2024. <https://www.news-medical.net/news/20110124/FDA-grants-pre-market-clearance-for-SBis-rHead-Extended-Stem.aspx>.

  • Chicago

    Evident Corporation - Life Sciences. "FDA grants pre-market clearance for SBi's rHead Extended Stem". News-Medical. https://www.news-medical.net/news/20110124/FDA-grants-pre-market-clearance-for-SBis-rHead-Extended-Stem.aspx. (accessed November 21, 2024).

  • Harvard

    Evident Corporation - Life Sciences. 2019. FDA grants pre-market clearance for SBi's rHead Extended Stem. News-Medical, viewed 21 November 2024, https://www.news-medical.net/news/20110124/FDA-grants-pre-market-clearance-for-SBis-rHead-Extended-Stem.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
2023 EVIDENT Organoid Conference to share the latest organoid innovations